Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market

Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market

Introduction
1. Study Objective
2. Scope of the report
3. Market Taxonomy
Study Assumptions and Abbreviations
1. Research Methodology
2. Secondary Research
3. Primary Research
4. SPSS Approach
5. Data Triangulation
Executive Summary
Global Industry Overview
1. Market Overview
2. Regional Synopsis
3. Industry Supply Chain Analysis
4. DROT
  1. Driver
  2. Restraint
  3. Opportunities
  4. Trends
5. Government Regulation: How they would Aid the Business?
6. Competitive Landscape
  1. AstraZeneca PLC
  2. Eli Lilly & Company
  3. Galmed Pharmaceuticals Ltd.
  4. GENFIT S.A.
  5. Novo Nordisk A/S
  6. Novartis AG
  7. PFIZER INC.
  8. Siemens Healthineers AG
  9. TAKEDA PHARMACEUTICAL COMPANY LIMITED
  10. Zydus Lifesciences Limited
7. SWOT Analysis
8. Comparative Analysis Of The Current Technologies
9. Company Share in The Market
10. Analysis of Strategic Initiatives Adopted by Key Players
11. Drug Type Analysis
12. Growth Forecast of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market
13. Patent Analysis
14. Recent Developments
15. Industry Risk Assessment
Global Outlook and Projections
1. Global Overview
  1. Market Value (USD Million), Current and Future Projections, 2024-2037
  2. Increment $ Opportunity Assessment, 2024-2037
  3. Year-on-Year Growth Forecast (%)
2. Global Segmentation (USD Million), 2024-2037, By
  1. Drug Type, Value (USD Million)
    1. Vitamin E and Pioglitazone
    2. Obeticholic Acid (OCA)
    3. Lanifibranor
    4. Semaglutide
    5. Resmetirom
    6. Aramchol
    7. Cenicriviroc
    8. Others
  2. End user, Value (USD Million)
    1. Hospital Pharmacies
    2. Retail and Specialty Pharmacies
    3. Others
3. Regional Synopsis (USD Million), 2024-2037
  1. North America, Value (USD Million)
  2. Europe, Value (USD Million)
  3. Asia Pacific, Value (USD Million)
  4. Latin America, Value (USD Million)
  5. Middle East and Africa, Value (USD Million)
Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
North America Market
1. Overview
  1. Market Value (USD Million), Current and Future Projections, 2024-2037
  2. Increment $ Opportunity Assessment, 2024-2037
2. Segmentation (USD Million), 2024-2037, By
  1. Drug Type, Value (USD Million)
    1. Vitamin E and Pioglitazone
    2. Obeticholic Acid (OCA)
    3. Lanifibranor
    4. Semaglutide
    5. Resmetirom
    6. Aramchol
    7. Cenicriviroc
    8. Others
  2. End user, Value (USD Million)
    1. Hospital Pharmacies
    2. Retail and Specialty Pharmacies
    3. Others
  3. Country Level Analysis, Value (USD Million)
    1. U.S.
    2. Canada
3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
Europe Market
1. Overview
  1. Market Value (USD Million), Current and Future Projections, 2024-2037
  2. Increment $ Opportunity Assessment, 2024-2037
2. Segmentation (USD Million), 2024-2037, By
  1. Drug Type, Value (USD Million)
    1. Vitamin E and Pioglitazone
    2. Obeticholic Acid (OCA)
    3. Lanifibranor
    4. Semaglutide
    5. Resmetirom
    6. Aramchol
    7. Cenicriviroc
    8. Others
  2. End user, Value (USD Million)
    1. Hospital Pharmacies
    2. Retail and Specialty Pharmacies
    3. Others
  3. Country Level Analysis, Value (USD Million)
    1. UK
    2. Germany
    3. France
    4. Italy
    5. Spain
    6. NORDIC
    7. Russia
    8. Rest of Europe
3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
Asia Pacific Market
1. Overview
  1. Market Value (USD Million), Current and Future Projections, 2024-2037
  2. Increment $ Opportunity Assessment, 2024-2037
2. Segmentation (USD Million), 2024-2037, By
  1. Drug Type, Value (USD Million)
    1. Vitamin E and Pioglitazone
    2. Obeticholic Acid (OCA)
    3. Lanifibranor
    4. Semaglutide
    5. Resmetirom
    6. Aramchol
    7. Cenicriviroc
    8. Others
  2. End user, Value (USD Million)
    1. Hospital Pharmacies
    2. Retail and Specialty Pharmacies
    3. Others
  3. Country Level Analysis, Value (USD Million)
    1. China
    2. Japan
    3. India
    4. Australia
    5. South Korea
    6. Vietnam
    7. Thailand
    8. Singapore
    9. Malaysia
    10. Rest of Asia Pacific
3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
Latin America Market
1. Overview
  1. Market Value (USD Million), Current and Future Projections, 2024-2037
  2. Increment $ Opportunity Assessment, 2024-2037
2. Segmentation (USD Million), 2024-2037, By
  1. Drug Type, Value (USD Million)
    1. Vitamin E and Pioglitazone
    2. Obeticholic Acid (OCA)
    3. Lanifibranor
    4. Semaglutide
    5. Resmetirom
    6. Aramchol
    7. Cenicriviroc
    8. Others
  2. End user, Value (USD Million)
    1. Hospital Pharmacies
    2. Retail and Specialty Pharmacies
    3. Others
  3. Country Level Analysis, Value (USD Million)
    1. Brazil
    2. Mexico
    3. Argentina
    4. Rest of Latin America
3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
Middle East & Africa Market
1. Overview
  1. Market Value (USD Million), Current and Future Projections, 2024-2037
  2. Increment $ Opportunity Assessment, 2024-2037
2. Segmentation (USD Million), 2024-2037, By
  1. Drug Type, Value (USD Million)
    1. Vitamin E and Pioglitazone
    2. Obeticholic Acid (OCA)
    3. Lanifibranor
    4. Semaglutide
    5. Resmetirom
    6. Aramchol
    7. Cenicriviroc
    8. Others
  2. End user, Value (USD Million)
    1. Hospital Pharmacies
    2. Retail and Specialty Pharmacies
    3. Others
  3. Country Level Analysis, Value (USD Million)
    1. GCC
    2. Israel
    3. South Africa
    4. Rest of Middle East & Africa
3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
Global Economic Scenario
1. World Economic Outlook
About Research Nester
1. Our Global Clientele
2. We Serve Clients Across World

Companies Dominating the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Landscape

The presence of major players such as AstraZeneca PLC, Eli Lilly & Company, Galmed Pharmaceuticals Ltd., Pfizer Inc., Genfit SA, Novo Nordisk A/S, Takeda Pharmaceutical Company Ltd., and Arcturus Therapeutics Inc. contributes to the highly competitive nature of the non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market. These players are pushing the boundaries of innovation, making sizeable investments in research and development to study new mechanisms and treatment options. Furthermore, strategic partnerships and collaborations enable these firms to consolidate resources, tap advanced technologies, and extend services to new markets.

In May 2024, SomaLogic entered into a license agreement with OncoHost to develop precision cancer diagnostics, leveraging SomaLogic's proteomics platform. While primarily focused on oncology, the technologies developed may have applications in other diseases, including NASH, by identifying relevant protein biomarkers. This milestone underlines how clinical progress, together with supportive regulatory initiatives, has reshaped the market, urging players to stay innovative in order to expand and thrive in the competition.

Here are some leading companies in the NASH therapeutics and diagnostics market:

AstraZeneca PLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Eli Lilly & Company
Galmed Pharmaceuticals Ltd.
GENFIT S.A.
Novo Nordisk A/S
Novartis AG
PFIZER INC.
Siemens Healthineers AG
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Zydus Lifesciences Limited

Browse Key Market Insights with Data Illustration:

Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Report 2037

In the News

In October 2024, Gilead Sciences announced plans to acquire CymaBay Therapeutics for USD 4.3 billion, aiming to expand its liver disease portfolio. CymaBay's lead candidate, seladelpar, is in late-stage development for primary biliary cholangitis and has potential applications in NASH treatment.
In April 2024, DD-Pharmatech received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for DD01, its investigational treatment for non-alcoholic steatohepatitis (NASH). This designation is intended to expedite the development and review process, addressing the significant unmet medical need in NASH treatment.
In March 2024, 89bio partnered with a Chinese contract development and manufacturing organization (CDMO) to construct an active pharmaceutical ingredient (API) facility dedicated to the commercial production of their metabolic dysfunction-associated steatohepatitis (MASH) candidate. This strategic move aims to ensure a reliable supply chain and support the anticipated global demand upon the drug's approval.

Frequently Asked Questions (FAQ)

In 2024, the industry size of non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics was USD 4.6 billion.

The global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market size was USD 4.6 billion in 2024 and is projected to reach USD 117 billion by the end of 2037, expanding at a CAGR of 28.1% during the forecast period, i.e., 2025-2037. In 2025, the industry size of non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics will be valued at USD 5.9 billion.

Key players in the market are AstraZeneca PLC, Eli Lilly & Company, Galmed Pharmaceuticals Ltd., Pfizer Inc., Genfit SA, Novo Nordisk A/S, Takeda Pharmaceutical Company Ltd., and Arcturus Therapeutics Inc among others.

The retail and specialty pharmacies segment is anticipated to lead the non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market during the forecast period.

North America is anticipated to offer lucrative prospects to companies in the non-alcoholic steatohepatitis (Nash) therapeutics and diagnostics market during the forecast period.

Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market - Top Companies and Manufacturers

Companies Dominating the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

Subscribe to Our Newsletters

Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market - Top Companies and Manufacturers

Companies Dominating the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics industry?

What is the outlook for the non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market?

Who are the major players dominating the non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics landscape?

Which segment will capture the significant market share for non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics by 2037?

Which region will provide more opportunities for the non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics business in the coming years?